127 related articles for article (PubMed ID: 2456288)
1. Plasminogen activation and lysis of blood clots induced by cells in vitro.
Knox P; Crooks S
J Cell Physiol; 1988 Jun; 135(3):467-73. PubMed ID: 2456288
[TBL] [Abstract][Full Text] [Related]
2. Cross-linking of alpha 2-antiplasmin to fibrin is a key factor in regulating blood clot lysis: species differences.
van Giezen JJ; Minkema J; Bouma BN; Jansen JW
Blood Coagul Fibrinolysis; 1993 Dec; 4(6):869-75. PubMed ID: 7511944
[TBL] [Abstract][Full Text] [Related]
3. Role of plasminogen, plasmin, and plasminogen activators in the migration of fibroblasts into plasma clots.
Knox P; Crooks S; Scaife MC; Patel S
J Cell Physiol; 1987 Sep; 132(3):501-8. PubMed ID: 2958486
[TBL] [Abstract][Full Text] [Related]
4. The roles of alpha 2-antiplasmin and plasminogen activator inhibitor 1 (PAI-1) in the inhibition of clot lysis.
Robbie LA; Booth NA; Croll AM; Bennett B
Thromb Haemost; 1993 Aug; 70(2):301-6. PubMed ID: 8236139
[TBL] [Abstract][Full Text] [Related]
5. Biochemical and biophysical conditions for blood clot lysis.
Sabovic M; Blinc A
Pflugers Arch; 2000; 440(5 Suppl):R134-6. PubMed ID: 11005642
[TBL] [Abstract][Full Text] [Related]
6. [Intensification of the effect of exogenous plasminogen activators on lysis of fibrin blood clots due to a decrease in the level of alpha-2- antiplasmin by a plasmasorption method].
Ogloblina OG; Saburova OS; Semenova OA; Belova LA
Biokhimiia; 1994 Jan; 59(1):62-8. PubMed ID: 7509643
[TBL] [Abstract][Full Text] [Related]
7. In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis--study in healthy subjects and correlation with blood fibrinolytic parameters.
Colucci M; Scopece S; Gelato AV; Dimonte D; Semeraro N
Thromb Haemost; 1997 Apr; 77(4):725-9. PubMed ID: 9134650
[TBL] [Abstract][Full Text] [Related]
8. Influence of factor XIIIa activity on human whole blood clot lysis in vitro.
Jansen JW; Haverkate F; Koopman J; Nieuwenhuis HK; Kluft C; Boschman TA
Thromb Haemost; 1987 Apr; 57(2):171-5. PubMed ID: 2440124
[TBL] [Abstract][Full Text] [Related]
9. Effect of retraction on the lysis of human clots with fibrin specific and non-fibrin specific plasminogen activators.
Sabovic M; Lijnen HR; Keber D; Collen D
Thromb Haemost; 1989 Dec; 62(4):1083-7. PubMed ID: 2515603
[TBL] [Abstract][Full Text] [Related]
10. Clot lysis mediated by cultured human microvascular endothelial cells.
Speiser W; Anders E; Binder BR; Müller-Berghaus G
Thromb Haemost; 1988 Dec; 60(3):463-7. PubMed ID: 3149047
[TBL] [Abstract][Full Text] [Related]
11. Correlation between progressive adsorption of plasminogen to blood clots and their sensitivity to lysis.
Sabovic M; Lijnen HR; Keber D; Collen D
Thromb Haemost; 1990 Nov; 64(3):450-4. PubMed ID: 2096491
[TBL] [Abstract][Full Text] [Related]
12. Turbulent axially directed flow of plasma containing rt-PA promotes thrombolysis of non-occlusive whole blood clots in vitro.
Tratar G; Blinc A; Strukelj M; Mikac U; Sersa I
Thromb Haemost; 2004 Mar; 91(3):487-96. PubMed ID: 14983224
[TBL] [Abstract][Full Text] [Related]
13. Studies on the specific fibrinolytic effect of human extrinsic (tissue-type) plasminogen activator in human blood and in various animal species in vitro.
Korninger C; Collen D
Thromb Haemost; 1981 Aug; 46(2):561-5. PubMed ID: 6795744
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of concomitant thrombin-mediated fibrin formation enhances clot lysis in whole blood.
Haskel EJ; Eisenberg PR; Abendschein DR
Blood Coagul Fibrinolysis; 1993 Feb; 4(1):7-13. PubMed ID: 8457655
[TBL] [Abstract][Full Text] [Related]
15. The role of fibroblasts in organization and degradation of a fibrin clot.
Mirshahi M; Azzarone B; Soria J; Mirshahi F; Soria C
J Lab Clin Med; 1991 Apr; 117(4):274-81. PubMed ID: 2010668
[TBL] [Abstract][Full Text] [Related]
16. Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis.
Jankun J; Aleem AM; Selman SH; Skrzypczak-Jankun E; Lysiak-Szydlowska W; Grafos N; Fryer HJ; Greenfield RS
Int J Mol Med; 2007 Nov; 20(5):683-7. PubMed ID: 17912461
[TBL] [Abstract][Full Text] [Related]
17. Platelet factor XIII increases the fibrinolytic resistance of platelet-rich clots by accelerating the crosslinking of alpha 2-antiplasmin to fibrin.
Reed GL; Matsueda GR; Haber E
Thromb Haemost; 1992 Sep; 68(3):315-20. PubMed ID: 1279832
[TBL] [Abstract][Full Text] [Related]
18. Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro.
Collen D; De Cock F; Demarsin E; Lijnen HR; Stump DC
Thromb Haemost; 1986 Aug; 56(1):35-9. PubMed ID: 3095946
[TBL] [Abstract][Full Text] [Related]
19. RGDFAP: platelet aggregation inhibitory and profibrinolytic hybrid peptide (RGDF coupled with the carboxy terminal part of alpha 2-antiplasmin) enhances plasminogen binding to platelets.
Udvardy M; Schwartzott D; Jackson K; Posan E; Rak K; McKee PA
Blood Coagul Fibrinolysis; 1995 Jul; 6(5):481-5. PubMed ID: 8589217
[TBL] [Abstract][Full Text] [Related]
20. The effect of flow on lysis of plasma clots in a plasma environment.
Sakharov DV; Rijken DC
Thromb Haemost; 2000 Mar; 83(3):469-74. PubMed ID: 10744155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]